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Abstract
Coronary balloon angioplasty and coronary stenting are the procedures used in
healing coronary artery disease. However, injury of arteries during angioplasty and
stenting causes cell stimulations in tissue. Cell movement and thrombosis lead to re-
narrowing of widened vessel called restenosis. Several new types of carriers and
technology have been developed to suppress and/or prevent restenosis via prevention
of migration/proliferation of smooth muscle cells (SMCs). The conventional ap‐
proaches are not fully effective for inhibiting restenosis. In order to eliminate such
problems, stent-based delivery methods are developed to replace traditional vascular
approaches. A series of materials have been improved for controlled delivery/release
of genes, miRNAs, peptide structures, siRNAs, miRNAs, and antisense molecules to
the target tissue. Agents to be delivered are either attached to the materials or
entrapped in polymeric structure. In particular, biodegradable polymers have held
great interests in drug delivery for targeting or prolonging implantable drug release.
This chapter summarizes the molecular mechanisms of in-stent restenosis, the role of
SMCs and endothelial cells in restenosis, and recent researches about the polymeric
materials featured in drug/gene carrier systems, nanovehicles, and stent coating
materials to prevent restenosis.
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1. Introduction
Atherosclerosis is a disease in which a plaque builds up inside your arteries. The plaque builds
up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque
hardens and narrows your arteries [1]. Arteries are blood vessels that carry oxygen-rich blood
to organs in the body, and this plaque limits the flow of oxygen-rich blood to organs and other
parts of body. Thus, atherosclerosis can lead to serious problems, including heart attack, stroke,
or even death. Percutaneous transluminal coronary angioplasty (PTCA) is a technique used to
widen the narrowing in a coronary artery without surgery.
2. What happens during angioplasty?
At the beginning, the doctor moves a guiding catheter into the artery with the blockage. Once
the guiding catheter is in right place, a guide wire is moved across the blockage site and then
a balloon catheter is moved to the blockage site. The balloon is inflated for a few seconds to
compress the blockage against the artery wall and then the balloon is deflated. This proceeding
can be repeated for a few times. Each time the balloon is pumped, the plaque widens a little
more and enables the blood to flow through. If it is needed, a stent is placed within the coronary
artery to keep the vessel open. Following this, the catheter is removed and the procedure is
completed, as seen in Figure 1. As a result, the narrowed artery is enlarged by PTCA. PTCA
is sometimes called coronary angioplasty. Coronary angioplasty has become increasingly
popular as a result of its low morbidity and mortality and reduced hospital stay in comparison
with surgery. Coronary angioplasty is generally effective and safe, but restenosis is frequent,
occurring in about 30-40% of cases [2]. Restenosis limits the long-term beneficial effects of
PTCA and related procedures. PTCA may be defined as the initial gain in artery lumen size,
and restenosis can be defined as the loss of gain. Prevention of restenosis after successful PTCA
remains one of the most challenging issues in the obstructive treatment of coronary artery
disease [3].
3. What causes restenosis?
As we mentioned above, stent placement is another option that is applied during angioplasty.
Stent is a metallic scaffold that keeps the narrowed coronary artery portion open. Besides, as
a metallic scaffold, the body may also perceive as alien. In fact, the trauma created by angio‐
plasty and stenting in tissue is more effective on restenosis. The trauma created by angioplasty
and stenting leads cell stimulations in tissue, triggers cells in that region, and causes cell
proliferation, migration, and thrombosis. Finally, cell movement and thrombosis lead to the
renarrowing of the vessel.
Restenosis following balloon dilation of the vascular endothelium is thought to occur in three
steps:
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1. Elastic recoil, which tends to occur within the first 24 h of the procedure
2. Thrombus formation, which occurs within the first 2 weeks
3. Neointimal hyperplasia involving smooth muscle cell (SMC) activation and synthesis of
extracellular matrix, which occurs over the course of the first 3 months [4]
Over 1.5 million percutaneous coronary revascularization procedures are performed annually
worldwide, most being intracoronary stenting. Clinically significant restenosis continues to
occur in ฀14% of elderly patients within the first year undergoing PTCA. Therefore, there are
great efforts for the prevention of restenosis [3]. For the prevention of restenosis, infusing a
drug in solution at the site of injured artery is a simple approach and is not successful because
of the rapid washout of infused drug from the arterial tissue. Almost 90% of infused drug is
lost within 30 min with almost complete loss occurs in less than 24 h [5].
4. Drug-Eluting Stent (DES)
Early difficulties with coronary stents included a risk of early thrombosis (clotting) resulting
in occlusion of the stent. Coating stainless steel stents with some other materials such as
platinum or gold were evaluated. However, this approach by itself did not eliminate the
problem. Then researchers coated stent surface with biocompatible polymers; moreover, the
idea of using these polymers as drug reservoir is generated. Scientists developed drug-eluting
stents and used the devices themselves as a tool for delivering medication directly to the
Figure 1. Balloon angioplasty and stent placement: (a) artery, (b) plaque formation, (c) balloon catheter at the blockage
site, (d) balloon inflation and stent placement.
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arterial wall. The medication is entrapped in polymer layers or loaded into polymeric nano‐
particles, and nanoparticles are embedded in polymeric layers. A drug-eluting stent consists
of three main parts.
The first part is the metallic scaffold. The metallic scaffold may be constituted by using different
types of metallic materials such as stainless steel, nitinol, cobalt, chromium, platinum, gold,
magnesium alloy, etc.
The second part is the drug-eluting polymer-coated inner surface of the scaffold. The polymer-
coated inner surface of the scaffold is generally used as a drug carrier, which holds and elutes
the drug in a controlled manner. The polymers used for DES is generally biodegradable
polymers like polylactic acid (PLA), polyglycolic acid (PLGA), and polycaprolactone (PCL).
Besides, nonbiodegradable polymers like polybutylmethacrylate (PBMA), polymethylmetha‐
crylate (PMMA), phosphorylcholine, and polyethylene terphthalate (PET) are also evaluated.
The third part is the medication that is released from stent directly to arterial wall. Drugs used
in DES are immunosuppressive and antiproliferative drugs like sirolimus, everolimus,
zotarolimus, paclitaxel, etc., to inhibit neointimal growth, which would cause restenosis [2].
Although the drug-eluting stents significantly reduced the rate of restenosis, it did not
completely eliminate restenosis, especially in complex lesions. Additionally, delayed endo‐
thelialization after drug-eluting stent implantation is considered to be the cause of late
thrombosis. Therefore, scientists have suggested that gene transfer can be an option to address
these problems by inhibiting proliferation of vascular smooth muscle cells (VSMCs) and by
promoting endothelialization with some genes [6]. Then scientists used stents as a tool to
deliver growth factors, plasmids, and antisense oligonucleotides directly to arterial wall.
Several studies have been carried out for the delivery and controlled release of genes encoding
antiproliferative proteins, miRNAs, peptide structures, and siRNAs to the target tissues
through different polymeric materials.
5. Gene therapy for the prevention of restenosis
Gene therapy is the use of genes as a means to achieve high levels of the therapeutic gene
product to treat acquired cardiovascular diseases. It can be used as a gene replacement strategy
to enhance normal protein function to correct genetic defects. Also, it can be used for local gene
transfer to provide a means of delivering a high concentration of therapeutic proteins at the
targeted tissue. The vectors used for gene delivery can be classified into two categories,
nonviral and recombinant viral vectors. Given the focus of this chapter on gene delivery
approaches, we will just briefly discuss the nonviral (polycationic) vector choices. A delivery
vehicle of either viral or nonviral origin is essential to carry the foreign gene into a cell. The
each of the vector choices has unique advantages and disadvantages.
Viral vectors take advantage of the easy integration of the target gene into the host and long-
term expression of gene. Immunogenicity is the major problem of using viral vectors in clinical
studies. Attention has turned therefore to nonviral vectors, which possess many advantages
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over viruses in terms of safety and ease of use, and many clinical studies have now been
performed using nonviral technology [7]. Although nonviral vectors are less efficient at
introducing and maintaining foreign gene expression compared to viral vectors, they have the
profound advantage of being nonpathogenic and nonimmunogenic [8]. Plasmid DNA is the
simplest gene delivery vector. In cell transfection, the minimum amount of negatively charged
naked plasmid can go by the cell membrane. Therefore, it is necessary to carry genetic materials
to target cell by a vector, which are commonly liposomes or polycationic materials.
In nonviral gene therapy, the negatively charged DNA is conjugated with a positively charged
cationic polymer. Nevertheless, the conjugate prepared has to be positively charged. By this
way, pDNA is wrapped in a protective envelope to be delivered. Once the conjugate is inside
the cell, pDNA expresses the targeted proteins to cure the target disease as seen in Figure 2.
Figure 2. Polycationic gene transfer.
Human gene therapy for the prevention of restenosis is expected to provide important
advances in therapeutic restenosis management. If applied in humans, it will be possible to
provide long-term beneficial therapeutic effects. However, some key issues, including vector
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safety and delivery mechanisms, still have to be resolved before percutaneous gene therapy
can be widely applied in clinic. With the aim of inhibition of restenosis, several new types of
carriers and technology have been developed, and a great number of gene therapy methods
have been studied.
Vascular gene transfer is used to overexpress therapeutically important proteins and correct
genetic defects. Promising therapeutic effects have been obtained in animal models of
restenosis via transfer of genes, such as encoding vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF), nitric-oxide synthase, thymidine kinase, tissue inhibitor of
metalloproteinases, etc. [9]. In vascular gene therapy, it is required to combine a therapeutic
gene or a therapeutic gene product with an appropriate vector. These complexes are delivered
to target cells from a device.
6. Catheter-mediated local gene transfer
Catheter delivery system is one of the devices used in vascular gene therapy. Several balloon
catheters (porous and microporous catheters, hydrogel catheters, dispatch catheters, and
infiltrator catheters) have been used for gene-based delivery. Rolland et al. [10] have investi‐
gated hydrogel-coated catheters for the delivery of interested drug and gene. In recent years,
Saurer et al. [11] have designed ultrathin multilayered polyelectrolyte films fabricated on
embolectomy catheter balloons by alternately adsorbing layers of a hydrolytically degradable
poly (β-amino ester) for the localized delivery of plasmid DNA to vascular tissue. Although
catheters seem to be a simple tool for gene delivery, several factors limit its efficiency. Most of
the catheters cause localized vascular injury with increased inflammatory response and
neointimal proliferation. Additionally, in direct injection method and catheter-based gene
delivery, transgene expression is limited within the injection site and homogenous expression
is not achieved. In point of fact, in stent-based gene delivery approach, a homogenous
transgene expression is achieved in comparison to catheter-based gene delivery methods.
7. Gene eluting stents
Stents represent an attractive alternative for targeted gene delivery, thanks to their permanent
scaffolding structure. Polymer-coated stents are used as delivery devices for the elongated
time release of small molecules. The greatest challenge with this delivery system lies in
achieving a compatible relationship between the stent, coating matrix, and vessel wall. As a
result of the long residence times of coatings on the stents, attention has been focused on using
them as reservoirs for prolonged local drug administration. While there is much known about
stent coatings for drug elution, less is known about the use of these substances for gene elution
[12]. The polylactic-polyglycolic acid copolymer (PLGA) is an FDA-approved, biodegradable,
and biocompatible polymer and is widely used in various drug release applications, as graft
materials in tissue engineering studies.
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Although the emergence of drug-eluting stents significantly reduced the rate of restenosis after
the interventions, it is not completely eliminated especially in complex lesions. Beside, delayed
endothelialization after drug-eluting stent implantation is reported and considered to be the
cause of late thrombosis, which is a critical complication. Gene transfer can be an option to
address these problems by inhibiting VSMCs proliferation, and with some genes, promoting
endothelialization [6].
Klugherz et al. [13] have developed stents coated with polylactic-polyglycolic acid copolymer
(PLGA), and they incorporated green fluorescent protein (GFP) plasmid DNA via emulsion
coating. They reported the first successful in vivo transfection using a DNA controlled-release
stent. GFP-encoding plasmid was efficiently expressed in rat aortic SMCs with 1% percent
efficiency. In later years, the same group developed an intravascular stent with a denatured
collagen-polylactic-polyglycolic acid for controlled release of GFP-encoding plasmid. Target
protein expression was determined with 10.8% efficiency. The level of expression was
significantly higher than previous study. They have concluded that denatured collagen
incorporated into plasmid DNA-stent coating formulation increased the target protein
expression via integrin-related mechanisms and associated changes in the arterial smooth
muscle cell actin cytoskeleton [14]. In another study, Takahashi et al. have developed metallic
stent-coated polyurethane emulsion containing plasmid DNA. They have evaluated in vivo
transgene expression levels, and they have reported that transgene expression has occurred
only in vessel segments in contact with the stent. Moreover, analysis of the GFP expression
pattern revealed a high frequency of marker protein-positive cells occurring at or near the
luminal surface. They have concluded that polymer-coated stents provide a new capability for
transgene delivery to immune cells that are believed to contribute to the development of in-
stent restenosis [15].
Walter et al. [16] have evaluated the delivery of human vascular endothelial growth factor
(hVEGF-2)-encoding plasmid delivery from a gene-eluting stent. They did not use a vehicle to
encapsulate the plasmid DNA, encoding for could achieve similar reductions in neointima
formation while accelerating, rather than inhibiting, re-endothelialization. They have found
that the lumen cross-sectional area (4.2 ± 0.4 versus 2.27 ± 0.3 mm2, P < 0.001) was significantly
greater and the percentage of cross-sectional narrowing was significantly lower (23.4 ± 6 versus
51.2 ± 10, P < 0.001) in VEGF stents compared with control stents implanted in hypercholes‐
terolemic rabbits [16]. In another study, Walsh et al. developed metallic stents coated with a
polyurethane emulsion containing plasmid DNA (plasmid-encoded marker genes, b-galacto‐
sidase, luciferase, and GFP), which were implanted by Takahashi et al. [15] in rabbit iliac
arteries to evaluate transgene delivery. They have observed transgene expressions only in
vessel segments in contact with the stent, and they have also emphasized that the extent of
transgene expression was dependent upon the quantity of DNA loaded onto the stent [15].
Nitric oxide (NO) is an important regulator of vascular cellular proliferation. NO promotes
EC growth and inhibits proliferation of SMCs in the vessel. Additionally, NO reduces platelet
adhesion and aggregation. ECs produce NO via nitric oxide synthase (NOS). Accordingly,
Bohl Masters et al. [17] have evaluated the effects of localized delivery of NO from hydrogels
covalently modified with S-nitrosocysteine (Cys-NO) on neoinitma formation in a rat balloon
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injury model. They have reported that localized the delivery of NO from hydrogels inhibited
neointima formation by approximately 75% at 14 days. Recently, Sharif et al. [18] have studied
therapeutic gene delivery from a stent. They have developed lipoplexes composed of lipofectin
and therapeutic eNOS gene. They have coated lipoplexes directly onto the surface of stents
and have demonstrated efficient gene delivery for 28 days via liposome-mediated gene
delivery.
In another study, Zhu et al. [19] have developed stent-coated dodecylated chitosan-plasmid
DNA nanoparticles (DCDNPs) and used them as scaffolds for localized and prolonged
delivery of reporter genes into the diseased blood vessel wall. As prepared DCDNPs were
spray coated on stents, and a thin layer of dense DCDNPs was successfully distributed onto
the metal struts of the endovascular stents. Both in vitro and in vivo expression levels of
plasmid DNA-encoding GFP were evaluated. In cell culture, DCDNP stents containing
plasmid EGFP-C1 exhibited high level of GFP expression in cells grown on the stent surface
and along the adjacent area. In animal studies, reporter gene activity was observed in the region
of the artery in contact with the DCDNP stents, but not in adjacent arterial segments or distal
organs. Thus, they have concluded that the DCDNP stent provides a very promising strategy
for cardiovascular gene therapy [19].
In recent years, Paul et al. [20] have developed a really functional nanobiohybrid hydrogel-
based endovascular stent device. The hydrogel was comprised of fibrin matrices, assembled
layer by layer on stent surface with alternate layers carrying endosomolytic Tat peptide/DNA
nanoparticles or nanoparticles hybridized to polyacrylic acid wrapped single-walled carbon
nanotubes. In vitro studies have demonstrated that CNTs incorporated in the hydrogel layers
play a major role in tuning the bioactivity of the stent. In addition, the developed stent
formulation can significantly reduce the loss of therapeutics while traversing through the
vessel and during deployment. In addition to all these, they have demonstrated that the
hydrogel-based scaffold carrying therapeutic gene significantly enhances the re-endotheliali‐
zation of injured artery via in vivo experiments compared to controls. In conclusion, they have
declared that this new technology is going to be very useful for controlled delivery of multiple
biotherapeutics from stent and other biomedical devices [21].
Since the long-term clinical studies of DES have reported high incidence of late thrombosis,
Yang et al. [22] have developed a drug and a gene containing system. They have coated the
stent with bilayered PLGA nanoparticles containing VEGF plasmid in the outer layer and
paclitaxel in the inner core. They have suggested that while re-endothelialization is going to
promote by early release of VEGF gene, slow release of Paclitaxel is going to suppress smooth
muscle cell proliferation. They have demonstrated that VEGF/Paclitaxel containing NP-coated
stents showed complete re-endothelialization and significantly suppressed in-stent restenosis
after 1 month compared to commercial DES [22].
Evidence about restenosis suggests that vascular injury during stent placement and angio‐
plasty procedure activates medial VSMCs, changing them from a quiescent to a proliferative
phenotype, and leads them to migrate from the media into the intima. Matrix metalloprotei‐
nases (MMPs) are zinc-dependent endopeptidases. They digest extracellular matrix compo‐
nents, and they play a major role in the formation of restenosis. It is well known that following
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angioplasty, MMPs are secreted increasingly. MMPs are secreted as zymogens. In normal
physiological vascular remodeling, the activity of MMPs is tightly regulated at the transcrip‐
tion level, the activation of their pro-form or zymogens, the interaction with specific ECM
components, and the inhibition by endogenous inhibitors. Tissue inhibitor of matrix metallo‐
proteinases (TIMPs) are the inhibitors of MMPs. Many MMPs and TIMPs are regulated at the
level of transcription by a variety of growth factors, cytokines, and chemokines [23]. The
interruption of MMPs activity by tissue inhibitor metalloproteinase infection has been shown
to limit SMC proliferation and migration through various models by researchers [24]. Local
gene transfer of tissue inhibitor of metalloproteinase-2 (TIMP-2) has been studied on a mouse
model. TIMP-2 recombinant adenoviruses overexpressing human TIMP-2 gene have been
transferred to SMCs, and the findings demonstrated significant decrease in vein graft diameter
[25]. Thus, VSMCs seem to be the most promising cell type to be targeted for inhibition of
restenosis. Recently, Laçin et al. [26] have used PEGylated nanoparticles poly(St/PEG-EEM/
DMAPM) monosized nanoparticles with significantly high cationic charge for the transfection
of TIMP-2-encoding plasmid to SMCs. Increased TIMP-2 protein expression in SMCs accord‐
ing to nontransfected SMCs confirmed the successful delivery and expression of the tissue
inhibitor of matrix metalloproteinase-2 (TIMP-2) gene via a nonviral transfection gene therapy
approach. This PEG-lated monosized, nontoxic, and highly positively charged nanoparticle
poly(St/PEG-EEM/DMAPM) was successfully used in SMCs transfection studies.
Polyethylene glycol (PEG) is the polymer of choice for nonviral vector systems because it
possesses several favorable properties such as the lack of immunogenicity, antigenicity, and
toxicity and a high solubility in water and in many organic solvents. The cytotoxicity of the
polycationic carriers used in gene therapy is an important consideration, especially when
polycations with high positive charge were used. Thus, to overcome the cationic polymeric
vector-induced toxicity, many researchers encapsulate genetic materials or drugs into a PEG
shielded cationic liposomal bilayer [27]. PEG is also approved by the FDA for human use.
PEGylation of a drug or a material helps to reduce its excretion by the kidneys and avoids its
degradation by proteolytic enzyme. Additionally, PEGylation prevents molecule from
reticuloendothelial (RES) clearance by enhancing the water solubility of the molecule and to
reduce its immunogenicity and antigenicity [28-30].
Cardiovascular gene therapy is the third most popular application for gene therapy. Although
preclinical studies of gene therapy studies for restenosis have shown promising results for the
potential application of the gene delivery methods in cardiovascular disease, numerous
cardiovascular gene therapy clinical trials have not demonstrated substantially positive results
for effective gene transfer. A major disappointing feature of the trials is that while preclinical
and uncontrolled phase-I gene therapy trials have been continued in a positive matter, none
of the randomized controlled phase-II/III cardiovascular gene therapy trials have shown
clinically relevant positive effects [31]. Low gene transfer efficiencies were observed with most
of trials. A sophisticated efficient delivery method for cardiovascular applications is still not
existing, and only low gene expression levels could be detected in target tissues [31]. Recently,
several delivery approaches have been designed for the treatment of restenosis, but a number
of challenging obstacles must be solved. For example, for different types of biomolecules
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(miRNA, siRNA, plasmid, peptide, etc.), different types of materials and different types of
vector systems are used. Therefore, it is important to develop unique gene delivery systems
that have enhanced transgene efficacy, are safe, and are clinically reliable.
8. Prevention of in-stent restenosis via other biomolecules and peptides
After coronary artery angioplasty (PCI, heart stent surgery), several biomolecules participate
in formation of cellular response. Leucocytes and thrombosites discharge cytokines and
growth factors inside the blood vessel, adventitia, and encompassing tissue after blood vessel
damage. It is well known that tumor necrosis factor α (TNF-α), platelet-derived growth factor
(PDGF), and transforming growth factor β (TGF-β) modulate cellular behaviors. Following the
activation and proliferation of smooth muscle cell by fibroblasts, significant cumulation and
response of extracellular matrix (ECM) in the vessel wall occur. Due to the responsibilities in
cellular interactions, ECM, the active component of the vessel wall, is known as a considerable
player in vascular diseases. The ECM consists of a diversity of molecules, including collagen,
elastin, glycoproteins, and proteoglycans.
Type III collagen is the most abundant matrix protein in a muscular coronary artery. MMPs
move through and interact with the C-terminus of the collagen molecule. Several MMPs attend
in the collagen degradation mechanism. Interstitial collagenases (MMP1, MMP8, and MMP13)
are the most prevalent MMPs that cleave fibrillar collagens, while gelatinases are active against
nonfibrillar collagen components of the ECM.
While some of the cytokines and growth factors such as uPA, MT-MMPs, IL-1, PDGF, and
TNF-α arrange MMP activation, TGF-β, heparin, steroids, and tissue inhibitor of metallopro‐
teinases (TIMP 1-4) inhibit MMP activity.
Besides, the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) are
also another biomolecule group related with atherosclerosis and possibly restenosis. Protease
family ADAMTS enzymes regulate ECM transformation by reducing versican (VCAN—a
large extracellular matrix proteoglycan) and procollagen-type matrix components. The
degradation of versican by ADAMTS-1 catalyses the migration of SMCs and intimal hyper‐
plasia. Also, ADAMTS-7 enables SMC migration and intimal thickening by degradation of
cartilage oligomeric matrix protein (COMP). ADAMTS [2, 3, and 14] involve in the removal of
N-terminal peptides from procollagen to form mature collagen. Due to their substrate
specificity, ADAMTS enzymes are considered as attractive pharmaceutical targets.
Devices having biomimetic surfaces coated with sequences of extracellular matrix proteins,
peptides, and enzymes could accelerate endothelial regeneration and prevent from both the
thrombic and proliferative effect after stent implantation. In around 25% of patients, th e
development of scar tissue underneath the covering of the course may be thick to the point
that it can block the bloodstream and produce a vital blockage. At the point when a stent is set
in a vein, new tissue becomes inside the stent, covering the struts of the stent. At first, this new
tissue comprises healthy cells to cover the blood vessel endothelium. This is a great impact in
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light of the fact that the improvement of typical covering over the stent permits blood to stream
easily over the stented territory without coagulating. Later, scar tissue may structure under‐
neath the new healthy coating [32].
Due to the mechanisms of restenosis after angioplasty operation, it is known that TGF-β
increases. Yamamoto et al. [33] studied on ribozymes to inhibit TGF-β by cleaving the targeted
gene. TGF-β gene demonstrates 100% homology among the human, rodent, and mouse
species. They built ribozyme oligonucleotides targeted to the sequence of the TGF-β gene and
used it in a rat balloon injury model. Ribozyme inhibits TGF-β mRNA in cultured VSMCs, and
using ribozyme oligonucleotides, TGF-β was inhibited, resulting in a significant reduction in
neointimal formation in a rat balloon injury model. They also modified ribozyme oligonu‐
cleotides containing phosphorothioate DNA and RNA targeted to the TGF-β gene. TGF-β
expression was decreased with modified ribozyme oligonucleotides. It was shown that the
selective blockade of TGF-β resulted in the inhibition of neointimal formation and reduction
in collagen synthesis. It was assumed that the modification of ribozyme oligonucleotide
pharmacokinetics would create potential therapeutic strategy for the treatment of cardiovas‐
cular disease related to high TGF-β.
Merrilees and colleagues [34] mentioned the importance of viscoelastic properties of vessel
wall. They concentrated on arterial matrix proteoglycans, which are related to increasing tissue
volume and atherogenicity. One of the basic stimulants of proteoglycans is transforming
growth factor β1 (TGF-β1). The aim of the researchers was to investigate the effects of dimin‐
ishing TGF-β1 and proteoglycan synthesis in vivo. They used rabbit with balloon catheter
damage treated with a TGF-β1 antisense phosphorothioate oligonucleotide connected in a
pluronic gel to the adventitia. Statistical information showed that intimal thickening and
proteoglycan synthesis were inhibited with the inhibition of TGF-β1antisense. These data
affirm a part for TGF-β1 in creating neointima and exhibit a particular impact on the combi‐
nation, appropriation, and gathering of proteoglycan matrix.
There has been extraordinary enthusiasm for the way of stents themselves and the methods
used to embed them as boosts for in-stent restenosis. Stent design, arrangement, length, and
measures of coronary stream have gotten significant consideration. Additionally, there has
been incredible enthusiasm for the stents coated with gradually eluting antirestenotic special‐
ists. The use of drug-eluting stents limits neointima hyperplasia. Pyrrole-imidazole (PI)
polyamide targeting TGF-β1 is one of the candidate agents for the drug-eluting stents. In one
study, the effects of PI polyamide targeting the TGF-β1 promoter in rat after balloon injury
were studied. PI polyamide was designed to connect with the TGF-β1 promoter and carried
out for 10 min after inducing balloon injury. Neointimal thickening and re-endothelialization
were analyzed [35]. TGF-β1 was significantly decreased with PI polyamide, targeting the
expression of TGF-β1 mRNA. Fibronectin and collagen were also affected after targeting. It
was understood from the research that synthetic PI polyamide has potential to extinguish
neointimal hyperplasia after arterial injury. It was assumed from the article that PI polyamide
targeting TGF-β1 could be coated on the stent for the prevention of in-stent restenosis as next-
generation drug-eluting stents [35]. Besides, the long-term benefit and safety of coated active
stents are crucial research field and should be examined extensively in further studies. The
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application of prohealing substances and antirestenosis drugs together as coated on stent
represents a diversified approach to reduce restenosis without an increased risk for stent
thrombosis [36].
The prevention of new techniques of in-stent restenosis such as peptide-loaded stents to inhibit
the biological reactions of the vessel wall gains greater importance in novel studies.
According to the previous studies in the 90s, it was found that fibrin-coated stents lessened
thrombogenicity. Baker et al. [37] loaded RGD peptide into fibrin-coated stents due to the
inhibition effect of RGD peptide on interaction between fibrinogen with platelets. They have
used those stents in an atherosclerotic rabbit model. Four weeks after stent implantation,
myointimal hyperplasia in coated and uncoated stent groups were measured and it was seen
from the analysis that the extension of myointimal hyperplasia in coated stent group was lower
than in the uncoated stent group. Vessel cross-sectional areas of coated stents also were lesser
than the uncoated stents. As a result, it was thought that RGD-loaded fibrin-coated stents have
prevented vascular complications after stent implantation.
Hong et al. [38] have estimated the advantage and controlling of angiopeptin in a porcine
coronary in-stent restenosis model. They have used forty pigs arranged in four groups in the
experiments. Out of the control group, the other three groups were treated respectively with
one-time treatment (200 μg angiopeptin) at the site of stent placement, continuous angiopeptin
over a 1-week period via a subcutaneous osmotic pump (200 μg/kg total dose), and combina‐
tion of both locally and systematically. In conclusion, this study has demonstrated that the
group applied with continuous subcutaneous treatment with angiopeptin after stent implan‐
tation significantly has reduced in-stent restenosis by inhibiting neointimal hyperplasia.
In 1999, a synthetic octapeptide, angiopeptin, was used to inhibit tissue response against
growth  factor,  insulin-like  growth  factor,  and  interleukin-1-mediated  endothelial  cell
adhesion.
Wiktor brand stents were coated with polyorganophosphazene. Researchers loaded angio‐
peptin into that biodegradable polymer and implanted the stent in porcine coronary arteries.
The group has indicated that angiopeptin increased lumen diameter and morphometric lumen
area in significantly as a percentage [39].
We can observe several studies in stent implantation area about local biomolecule delivery
made since 1999. Coating of stent is necessary for carrying, prolongation, and elution of the
drug through the targeted area effectively and without any loss arising from catheter. Studies
on physical strengths of polymers coated on stents and eliciting inflammatory reactions
occurring after operation are still ongoing. A portion of the presently accessible gadgets,
coatings, and stents are drawing near to making this point an achievable reality. Stent
thrombosis remains an important problem after the implantation of different stent types.
Coating of stents impacts thrombogenicity. Simple chemical coating lessens platelet adhesion,
fibrinogen binding, and effectual against in-stent restenosis in clinical trials. Fuchs et al. [40]
were also interested in solving this problem about thrombosis with vasoactive agents. They
studied on in vitro and in vivo effects of C-type natriuretic peptide (CNP) that has dual effects
on different cell types in a porcine restenotic model. Although gene transfer of CNP in cultures
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of porcine vascular cells had achieved 30% reduction of growth of SMCs, the suppression of
endothelial growth using CNP had failed. Usage of the CNP gene could be a solution for
compress formation of restenosis while preventing late thrombosis [40].
Recent evidence point out endocrine activities are mediated by growth hormone. Shu and
colleagues made studies on Ghrelin, a 28-amino acid peptide, which had been isolated from
both human and rat stomach that was mediated by growth hormone secretagogue receptor.
Ghrelin is expressed in stomach tissue and has several important physiological effects in
secretion of growth hormone, inflammation, cell proliferation, differentiation, and apoptosis.
Besides, it has wide role on cardiovascular system, such as increasing myocardial contractility,
improving cardiac function, inhibiting ventricular remodeling, and attenuating cardiac
ischemia-reperfusion injury. Novel studies indicated inhibition of ghrelin on vascular inflam‐
mation and proliferation of VSMCs. It also repairs endothelial cells, promotes vascular
endothelial function, inhibits platelet aggregation, and exerts antithrombotic effects. Volante
et al. [41] had found its protective effect on vascular endothelial function by increasing
endothelial nitric oxide synthase (eNOS) expression and improving endothelial function.
Another research group has also stated that ghrelin has prevention against platelet aggrega‐
tion, MCP-1 expression, and exerts antithrombotic effects. Consequently, ghrelin is considered
as therapeutic candidate for the prevention and treatment of ISR [42].
In the 2000s, subjects on expanded polytetrafluoroethylene-covered stent-graft have been
carried out. Hamm et al. [43] have used 15-amino acid peptide (P-15), which had cell adhesion
property in supporting the endothelization on inner surface after implantation. The recovery
of a utilitarian endothelium over the surfaces of the embedded gadgets may restrain both the
thrombotic and proliferative reaction after gadget implantation. It was discovered from studies
that matrix proteins such as collagen and laminin could improve and increase endothelial
regeneration. Starting from this idea, P-15 synthetic peptide, which had cell binding cell of
collagen [44], has been tried in in vitro studies with endothelial cells [45]. It was shown that
cell migration and adhesion had increased on P-15-coated surface. According to those
experiments, P-15 peptide-coated stents had been used in clinical applications. P-15 peptide-
coated stents had demonstrated that similar healing with uncoated stents had provided high
luminal support and protected from distal emboli. Based on the results from this preparatory,
it was figured out that a peptide-treated stent is an alluring methodology for the treatment of
stenosed saphenous vein grafts [43].
A different approach with angiotensin-[1-7], an endogenous, biologically active peptide, has
come from Langeveld et al. [46]. Angiotensin-[1-7] is a part of the renin-angiotensin system,
which has vasodilatory, antithrombotic, and antiproliferative properties. The effects of
angiotensin-[1-7] infusion on neointimal formation after stent placement in male Wistar rats
have been investigated in this study. Other than the control group, angiotensin-[1-7] [24 g/kg
per hour) had been given to rats that underwent stent implantation in the abdominal aorta or
sham surgery by placing an osmotic minipump. The endothelial function has been measured
in isolated thoracic aortic rings after 4 weeks by histomorphometric and histological analyses.
Researchers have found out that angiotensin-[1-7]-treated group has exhibited a significant
decrease in neointimal thickness, neointimal area, and percentage stenosis compared with the
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control group [46]. Results have showed that angiotensin-[1-7] treatment has reduced neoin‐
timal formation after stent implantation in rats. This consequence has supported the idea of
Ang-[1-7] could be an alternative to the presently available aggressive antiproliferative drug-
loaded stents [46].
Yu et al. [47] were interested in calcineurin/nuclear factor of activated T cells (NFAT) axis. It
plays an important role in VSMCs that inhibits NFAT. In earlier studies, the main epitope site
on NFAT for calcineurin was discovered. The optimization of this site had induced to the
exploration of synthetic peptide VIVIT. Yu et al. [47] have used VIVIT to examine the inhibition
NFAT activation and NFAT-mediated proliferation and inflammation in RAW 264.7 macro‐
phages, Ea.Hy.926 endothelial cells and VSMCs, and blocked ionomycin-elicited nuclear
import of NFAT. It was also found that VIVIT suppressed platelet-derived growth factor-BB
(PDGF-BB) and thrombin induced VSMC proliferation. According to the data, it was reported
that NFAT is a regulator of PDGF-BB induced vSMC proliferation. This study stents coated
with VIVIT could be a candidate to more specific approaches in the antirestenosis therapy.
In parallel with the ongoing experiments, integrin-binding cyclic Arg-Gly-Asp peptide
(cRGD)-loaded stents were used to bound coronary neointima formation and to increase
endothelialization by attracting endothelial progenitor cells. It has been stated again that stent
coating with cRGD may be useful for reducing in-stent restenosis by accelerating endotheli‐
alization [48]. Another study was about RGD-modified liposomes targeted to integrin
GPIIbeIIIa on activated platelets [49]. RGD-conjugated liposomes have also been tested in vivo
in a rat carotid injury model. As seen from the experiments, cyclic RGD liposomes have binded
activated platelets significantly higher compared to linear RGD liposomes. Huang et al. [49]
have found an approach on optimization of platelet-targeting ability of ligand-modified
liposomes. It has been thought to be a solution for sensitive and selective delivery of thera‐
peutic agents in cardiovascular diseases such as atherosclerosis, thrombosis, and restenosis
where activated platelets play significant role in disease development, progression, and
outcome.
In-stent restenosis is a pathobiologic methodology, histologically different from restenosis
after balloon angioplasty and embodied generally of neointima arrangement. Since percuta‐
neous coronary mediation progressively includes the utilization of stents, in-stent restenosis
is moreover getting to be correspondingly more regular. Novel applicable and therapeutic
approaches in humans for re-endothelialization are about coating of stents with some sub‐
stances to give acceleration for the formation of endothelial coverage safely. It was indicated
in a porcine model study that cRGD-coated stents expedite endothelialization [50].
In a novel study, it has been focused on the binding ratio of integrin receptor to subendothelial
matrix proteins. When integrin binds to arginine-glycine-aspartic acid (RGD) peptide, it
imitates naturally occurring adherent interactions. The surface modification of stents with
RGD peptide also contributes selectivity for integrin alpha V beta 3, which stimulates endo‐
thelialization after stent implantation. Joner and colleagues [51] studied on the availability of
RGD peptide-loaded titanium-oxide nitinol stents. Functionality of the engrafted RGD peptide
has been examined by in vitro endothelial bioassays, and a subsequent 7-day in vivo endo‐
thelialization has been studied by using cRGD-coated self-expanding nitinol stents in rabbits.
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Significant increase in endothelial coverage with cRGD stent implants has been stated. This
study has represented as an innovative strategy to improve endothelialization and to catalyze
vascular healing after stent implantation [51].
Besides, Kramer et al. [52] insisted on interventional cardiology was revolutionized by stent
implantation. Stents were developed with antiplatelet therapy and new materials. They have
defended the importance of oral drug usage with newly developed stents together. Angio‐
tensin II (Ang II) is an important vasoactive peptide associated with in-stent restenosis, which
is produced locally from vessel wall. Due to the Ang II AT1 receptors’ effects on relationship
of Ang II with growth and inflammatory signals, A T1-receptor blocking drugs are widely
used to treat hypertension and heart failure [53]. Experimental clinical trials has estimated the
effect of AT1-receptor blockers on ISR but no significant result was obtained from patients who
were treated with drugs [52].
Different treatment about the movement, growth, and adhesion of endothelial cells has been
tried to improve the re-endothelization of stents. Yin and colleagues [54] had synthesized
muscle adhesive polypeptide mimics including dihydroxyphenylalanine and l-lysine
(MAPDL). They had attached MAPDL on ethylene vinyl acetate (EVA)-coated stent with
different molecular weight PEG spacers to find out optimum cell bioactivity. According to in
vitro analysis, endothelial cells layer formation had significantly increased on the MAPDL-
EVA-coated stents in contrast with the control bare stent. In this manner, it was demonstrated
that MAPDL-coated EVA surface had decrease platelet adhesion and appeared to be promising
solution for re-endothelialization of intravascular stent devices.
As is seen from the experiments, metal-based stents are mostly preferred for coronary artery
disease. The recovery of endothelium around the lesion site can be achieved by coating stents
with bioactive molecules. Due to restrictions in availability of proper bioactive signals that
would selectively stimulate growth of endothelium and immobilization of such signaling
molecules on the metal surface, Ceylan et al. had developed self-assembly, pH-dependent,
Dopa-conjugated peptide amphiphile and REDV-conjugated peptide amphiphile nanofibers.
Those nanofibers had mimicking property of native endothelium extracellular matrix and had
been easily immobilized on stainless steel surface. In vitro experiments had showed that
peptide nanofiber-coated stainless steel surface had increased adhesion of vascular endothelial
cells as against uncoated surface. Besides, it had decreased viability, proliferation of vascular
endothelial cells, and platelet attachment to the peptide. It was suggested in this study that
this bioactive stent design has provided a futuristic approach for clinical use in prolonged
cardiovascular treatments [55].
9. The role of small RNAs in-stent restenosis
Recent progress in molecular biology has resulted in development of numerous effective gene
therapy methods via transferring RNA molecules for the treatment of variety diseases. There
are also many studies with the purpose of prevention and treatment of vascular neointima
proliferation after balloon angioplasty and stent implantation, using RNA molecules [56-58].
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Recent studies suggest that microribonucleic acid-based (miRNA) are important gene regula‐
tors and seems to be suitable for the treatment of various cardiovascular diseases [56, 59].
Delivery and controlled release of miRNA through different polymeric materials to target
tissues is one of the nucleic acid-based therapy approaches.
Discovered little more than decade ago, non-protein-coding RNAs are single-stranded
endogenous RNAs, approximately 25 nucleotides long and they are called as miRNAs [60,
61]. They regulate gene expression negatively at the posttranscriptional level by binding to
specific mRNA target, leading either to degradation or to translational target protein repres‐
sion, rarely they can promote gene expression [56, 59, 62-64]. Small interfering RNAs (siRNA)
are short, double-stranded RNAs (20-25 nucleotides) that induce the degradation of target
mRNA and inhibits the production of the target protein, and the procedure is called RNA
silencing. Unfortunately, clinical applications of RNA interference-based therapeutics such as
siRNAs and miRNAs have been limited mainly due to low intracellular delivery efficiency in
vitro and in vivo. However, RNA molecules promising therapeutic potential, safe, and efficient
delivery methods have to be developed for targeted controlled release. Over the last decade,
there has been great effort to develop effective nonviral delivery systems for the transfection
of siRNA and miRNA [60]. As it is well known, RNAs are short double-stranded molecules.
Due to this reason, they have more rigid structures and inappropriate distribution, making
them difficult to form stable and compact particles using a wide range of cationic condensing
reagents, such as polylipids, polypeptides, and polyamines, via simple electrostatic interac‐
tions. Thus, to achieve maximum target gene silencing, improved gene carrier systems have
to be prepared. Therefore, attention has become focused on development of nonviral gene
delivery vectors to carry small RNA molecules to target cells [65].
Several experimental and clinical data showed that miRNAs are associated with resteno‐
sis  or  renarrowing  of  the  arteries  which  primarily  results  from  the  proliferation  and
migration of VSMCs into the intima after stent implantation [66, 67]. Recent evidence by
several  groups  has  decelerated  that  miRNAs  have  an  important  role  in  prevention  of
atherosclerosis and restenosis [62, 63, 67-71]. In fact, knockdown of miR-21, miR-221, and
miR-222 and overexpression of  miR145 were found to be intimately relevant to neointi‐
mal formation after vessel injury [57, 58, 62, 71-73]. miR-21 is encoded by a single gene and
autonomously transcribed from a conserved promotor that is located within the intron of
the  overlapping  protein  coding  gene  [73].  The  oncogenic  activity  of  miR-21  has  been
identified by several groups [74-76]. Besides, it has been found to play important role in
proliferation of VSMCs, cardiac cell growth, and death and cardiac fibroblast functions [73].
Indeed, both basic and clinical studies have demonstrated that the overexpression of miR-21
in  human  reduces  cardiac  fibrosis  and  prevents  vascular  neointima  proliferation  after
balloon angioplasty and stent implantation [72, 77].
Similarly, Liu et al. reported that both of miR-221 and miR-222 were recognized in rat carotid
arteries after angioplasty, in which their expression was upregulated and localization in
VSMCs at the injured regions of vascular walls [78]. Moreover, it was shown that the overex‐
pression of miR-221 and miR-222 decreased VSMC proliferation in vitro. Also, the knockdown
of miR-221 and miR-222 in rat carotid arteries suppressed VSMC proliferation in vivo and
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neointimal lesion formation after angioplasty [78]. However, among miRNAs, miR-145 is the
most abundant type in vascular walls [58]. In addition to these, especially both miR-143 and
miR-145 are significantly expressed in vascular endothelial cells (VECs), which is able of
controlling vascular neointimal lesion formation [57].
siRNAs mediate specific gene silencing through a highly regulated enzyme-mediated process.
Nowadays, siRNAs are established as the most important biological strategy for gene silencing
that includes the degradation of target mRNA and block production of the related protein [79,
80]. Yanming et al. [81] have found that siRNAs reduce neointima formation significantly as
reflected by a decreased intima/media area ratio in carotid artery sections after surgical
mechanical injury of the rat carotid artery. Wang et al. [59] reported that c-myc siRNA, when
given immediately after the surgery, is an effective approach for the prevention of vein graft
restenosis.
Usage of nanoparticle eluting stent technologies is an important approach. Walter and
colleagues [16] have developed nanoparticles containing plasmid DNA-encoding sequence
hVEGF-2 and explored the ability of delivery of target sequence by NP through the stent. An
alternative and novel treatment strategy, acceleration of re-endothelialization via VEGF-2
gene-eluting stents, is achieved through endothelial cell proliferation by serving to activate
endothelial cell proliferation pathways [16, 82].
Strategies for enhancing gene delivery and gene transfer through stents typically involve the
complexations of siRNA/miRNA molecule with cationic polymers, which can be loaded on
the stent surface [82, 83].
Although there are several in vitro gene therapy studies for the prevention of restenosis, a few
studies with the use of miRNA/siRNA-based therapy for the treatment of cardiovascular
diseases have been carried out in humans. Although in vivo studies of miRNA-based agents,
conjugated to biodegradable polymers or encapsulated in nanoparticles, were promising, to
date there have been a few studies consisting of miRNA-vehicle complexes to a polymer-coated
stent that allow delivery of the miRNA for achieve endothelial cell proliferation by serving to
activate endothelial cell proliferation pathways [62, 82].
Patil and Panyam [84] have developed nanoparticles using the biodegradable polymer,
poly(d,l-lactide-co-glycolide) (PLGA), for siRNA delivery. Additionally, they have incorpo‐
rated in the PLGA matrix, a cationic polymer, polyethylenimine (PEI), to improve siRNA
encapsulation in PLGA nanoparticles. The effectiveness of siRNA-loaded PLGA-PEI nano‐
particles was investigated in vitro. They have reported that PEI in PLGA nanoparticle matrix
has increased siRNA encapsulation by about 2-fold and also improved the siRNA release
profile. Moreover, they have observed higher cellular uptake and cytosolic delivery with the
encapsulated siRNA.
In order to avoid such blockages, at the site of angioplasty or stent placement, the suppression
of SMCs near the implanted stent, etc., has developed a new delivery technique for Akt1 (Akt1
is a protein that plays a key role in cellular proliferation) siRNA nanoparticles to release from
a hyaluronic acid (HA)-coated stent surface. For this purpose, they have used disulfide cross-
linked low molecular polyethyleneimine (PEI) (ssPEI) as a gene delivery carrier. Disulfide
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bonds are stable in an oxidative extracellular environment but degrade rapidly in reductive
intracellular environments. They have immobilized Akt1 siRNA/ssPEI nanoparticles (ASNs)
on the HA-coated stent surface. They have reported that the Akt1 released from the stent
suppressed the growth of the smooth muscle at the peri-stent implantation area in the balloon-
injured external iliac artery in rabbits [85].
Encouragingly, the current developments in the understanding of RNAs have reveal both
miRNAs and siRNAs as a potential targets for the development of new diagnostic and
therapeutic strategies for the prevention of restenosis [56, 62, 63]. Therefore, attention has
become focused on the development of chemically modified RNAs to cure or prevent in-stent
restenosis.
10. Conclusion
As conclusion, platelets are the main reason for the formation of thrombus. After stent
implantation, platelets are activated and stimulate SMCs migration. In-stent restenosis occurs
by the proliferation of SMCs to the injury site. In future studies, the blood flow can be
improved, and no platelets are aggregated by coating and biomolecule loading instead of
loading to the stent surface.
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